Aravind Ganesh

#CJNS #PromotedArticle #FirstView -Automatic Matching Algorithms to Identify Eligible Participants for Stroke Trials: A Proof-of-Concept Study- doi.org/10.1017/cjn.20… #ClincalTrials #Neurology @SocCdnNSx #CSCN #CACN @TheCSNR @CSC_Stroke #CNSF @CNSFNeurolinks @CambUP_Psych

🩺 Why DOSE? The #DOSETrial is evaluating both low-dose (0.18mg/kg) and standard-dose (0.25 mg/kg) tenecteplase to find the safest, most effective approach in patients within <48h DOAC intake. Critical gap. Adaptive answers. #Stroke #Thrombolysis #ACTGlobal

🚨 Excited to launch the official X account for the DOSE Trial! DOAC associated Stoke Thrombolysis Optimization (DOSE) Trial is now recruiting across international sites. Follow us for real-time updates, milestones, and insights. #StrokeResearch #Thrombolysis #ACTGLOBAL

🚨 In this worldwide Practice Current survey of neurologists on mgmt of MCI, there was cautious optimism re: anti-amyloid therapies, with concerns about side effects but a general interest to prescribe: neurology.org/doi/10.1212/CP… @GrahamAMcLeod, Aaron Switzer, Eric Smith @DCNSNeuro

The Canadian Outcome Scale for Minor Stroke (COSMOS): a much-needed, novel 7-point scale to assess more Individualized outcomes in patients with minor stroke (mRS is not sufficient). @StrokeAHA_ASA Kudos to @mayank_G0 @draravindganesh Salome and team. ahajournals.org/doi/10.1161/ST…

“We're putting that lens on this lifespan trajectory of how risk and resilience manifests in congenital heart disease (CHD) over the life course.” The effects of CHD on the brain are not well understood. Dr. Thalia Field wants to change that. #BeatStroke #StrokeMonth

In adults with myasthenia gravis, treatment with intravenous inebilizumab, a CD19-specific monoclonal antibody, significantly improved function and reduced disease severity at 26 weeks. Full MINT phase 3 trial results and Research Summary: nej.md/4j8TiUo

Dr. @nishita_singh3 aims to revolutionize stroke causes and treatment. From her experience working in rural India to the day she came to Canada, Dr. Singh has been advocating and working towards equitable, life-saving stroke treatments in Canada and globally. #StrokeMonth

🚨In our latest blog post, Jaanya Lal discusses what happens in our brains when our immune system turns against us, “From Defence to Danger”: letsgetproof.com/blog/defence-t…

Thank you to Muse Laroyia and Dr. Bhavini Gohel for their advocacy around climate change and neurological health. "Wildfire smoke can harm your brain, not just your lungs" theconversation.com/wildfire-smoke… via @ConversationCA @UCalgaryMed

🚨🧠Reflections and comments on our study of brain frailty and stroke severity in @AANmember @GreenJournal @joachimfladt @DCNSNeuro neurology.org/doi/10.1212/WN… Thank you @NeurologyToday!

🚨 Multiple Sclerosis is a neuro disease for which med research has made major strides over the past decades. Check out our latest blog post from Arshdeep Bhullar on Clinical Manifestations, Diagnosis & Clinical Course of MS! (therapeutics post to follow) letsgetproof.com/blog/multiple-…

#ESOC2025 Session Report: #BloggingStroke contributor @chris7ianb shares highlights from session "Intravenous Thrombolysis in Acute Ischemic Stroke: Expanding Indications and Evidence." ahajournals.org/do/10.1161/blo… #stroke #AHAJournals @ESOstroke @draravindganesh @LinaPalaiodimou

🚨What if you could get a measure of someone's atherosclerotic burden right from a plain CT scan? Our pilot study on Arterial Brain Calcium (ABC) volume- a marker of athero & future stroke risk on non-contrast CT- now out in @JSCVD2: sciencedirect.com/science/articl… @dianajyk @DCNSNeuro

🚨Frailty and Stroke 🧠- this @WorldStrokeOrg Scientific Statement emphasizes the importance of conducting stroke trials in frail populations to inform evidence-based care: journals.sagepub.com/doi/10.1177/17… Thanks @nr_evans for leading this work! @DrTerryQuinn @DorcasGandhi and many others

We truly appreciate the superb efforts, support, and guidance of our Canadian colleagues, Steering Committee & study team in successfully completing this trial. @magdyselim @johneikelboom @mike_sharma2 @amyyu_md @draravindganesh @VancouverStroke @lucianacatanese @demchuk_andrew

Kudos to @ArKatsanos for his effective leadership of CoVasc-ICH! This Canada-led first RCT testing colchicine in acute ICH has provided the requisite feasibility metrics to effectively plan our global phase III trial, CoVasc-ICH 2 (phri.ca/research/covas…). Stay tuned!